Department of Otolaryngology, Zhuji People's Hospital, Zhuji City, Zhejiang Province, China.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):127-138. doi: 10.26355/eurrev_202101_24375.
Nasopharyngeal carcinoma (NPC) is a common cancer with high incidence in Southern China. Taxol is one of the first-line chemotherapeutic drugs for treating NPC; however, Taxol resistance has become the main difficulty for clinical treatment and the mechanisms remain not fully understood. In this study, we mainly focus on exploring whether exosomes from Taxol-resistant NPC cells played some roles in the resistance and progression of NPC.
Taxol was used to treat NPC cell line CNE1 and Taxol-resistant NPC cell line CNE1-TR cells to measure cell viability and IC50 by CCK-8 assay. Exosomes from these two cells were extracted and identified by transmission electron microscopy (TEM), and special protein markers were determined by Western blot (WB) assay. Real-time PCR was performed to detect levels of mRNAs in exosomes, CNE1 and CNE1-TR cells. WB was performed to detect protein levels. The p-DDX53 and si-DDX53 were constructed and cloned into cells, resulted with DDX53 overexpression and inhibition, then resistant associated protein levels and IC50 were measured. Finally, GW4869, an inhibitor to block exosome secretion, was used to verify that the exosomes derived from CNE1-TR cells transferred DDX53 to CNE1 cells and contributed to promote NPC resistance.
We found that the IC50 to Taxolin CNE1-TR was much higher than that in CNE1 cells and DDX53 was highly expressed in Taxol-resistant CNE1-TR cells. Furthermore, exosomes were successfully extracted and determined, showing high levels of DDX53 and MDR1. Thus, they could promote cell resistance for CNE1 after adding CNE1-TR exosomes into CNE1 cells. Moreover, DDX53 overexpression increased the IC50 and upregulated MDR1 in CNE1 cells, while DDX53 inhibition showed the opposite results. In addition, the DDX53 inhibition decreased the IC50 and repressed MDR1 in CNE1-TR cells. Besides, blocking exosome released from CNE1-TR by using GW4869 treatment significantly repressed the levels of DDX53 and MDR1, and the IC50 of CNE1 cells was reversed. Finally, the increased levels of MDR1 were significantly reversed following with adding DDX53 si-DDX53-CNE1-TR exosomes, and the increased IC50 to Taxol was obviously reversed.
This study firstly discovered that DDX53 was highly expressed in Taxol-resistant NPC cells, which could be transferred into normal NPC cells via exosome secretion. The transferred DDX53 could upregulate the expression of MDR1 in NPC cells to promote the resistant capacity to Taxol, which provided a novel insight for understanding NPC and might be a potential therapeutic target for NPC.
鼻咽癌(NPC)是一种在中国南方高发的常见癌症。紫杉醇是治疗 NPC 的一线化疗药物之一;然而,紫杉醇耐药已成为临床治疗的主要难点,其机制仍不完全清楚。在本研究中,我们主要关注探讨来自紫杉醇耐药 NPC 细胞的外泌体是否在 NPC 的耐药和进展中发挥了作用。
用紫杉醇处理 NPC 细胞系 CNE1 和紫杉醇耐药 NPC 细胞系 CNE1-TR 细胞,通过 CCK-8 测定法测量细胞活力和 IC50。通过透射电子显微镜(TEM)提取并鉴定这两种细胞的外泌体,并通过 Western blot(WB)测定法确定特殊的蛋白质标记物。通过实时 PCR 检测外泌体、CNE1 和 CNE1-TR 细胞中 mRNAs 的水平。通过 WB 检测蛋白水平。构建并克隆 p-DDX53 和 si-DDX53,使 DDX53 过表达和抑制,然后测量耐药相关蛋白水平和 IC50。最后,使用 GW4869(一种阻断外泌体分泌的抑制剂)验证来自 CNE1-TR 细胞的外泌体将 DDX53 转移到 CNE1 细胞并有助于促进 NPC 耐药。
我们发现 CNE1-TR 细胞中 Taxol 的 IC50 远高于 CNE1 细胞,并且 DDX53 在紫杉醇耐药的 CNE1-TR 细胞中高表达。此外,成功提取并确定了外泌体,显示出高水平的 DDX53 和 MDR1。因此,在将 CNE1-TR 细胞的外泌体添加到 CNE1 细胞后,它们可以促进 CNE1 细胞的耐药性。此外,DDX53 过表达增加了 CNE1 细胞的 IC50 并上调了 MDR1,而 DDX53 抑制则表现出相反的结果。此外,DDX53 抑制降低了 CNE1-TR 细胞的 IC50 并抑制了 MDR1。此外,使用 GW4869 处理阻断 CNE1-TR 细胞中释放的外泌体显著抑制了 DDX53 和 MDR1 的水平,并且 CNE1 细胞的 IC50 被逆转。最后,添加 DDX53 si-DDX53-CNE1-TR 外泌体后,MDR1 的水平显著逆转,对 Taxol 的 IC50 明显逆转。
本研究首次发现 DDX53 在紫杉醇耐药 NPC 细胞中高表达,可通过外泌体分泌转移至正常 NPC 细胞。转移的 DDX53 可上调 NPC 细胞中 MDR1 的表达,促进 NPC 对紫杉醇的耐药性,为理解 NPC 提供了新的视角,并可能成为 NPC 的潜在治疗靶点。